The Role of Immune Cells in the Pathogenesis of Connective Tissue Diseases-associated Pulmonary Arterial Hypertension

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2024 Oct 2

PMID 39355239

Authors

Zhe Li

Juan Ma

Xuejing Wang

Liquan Zhu

Yu Gan

Baoquan Dai

Affiliations

Soon will be listed here.

Abstract

Connective tissue diseases-related pulmonary arterial hypertension (CTD-PAH) is a disease characterized by an elevated pulmonary artery pressure that arises as a complication of connective tissue diseases. The number of patients with CTD-PAH accounts for 25.3% of all PAH patients. The main pathological features of CTD-PAH are thickening of intima, media and adventitia of pulmonary arterioles, increased pulmonary vascular resistance, autoimmune activation and inflammatory reaction. It is worth noting that abnormal immune activation will produce autoantibodies and release cytokines, and abnormal immune cell recruitment will promote inflammatory environment and vascular remodeling. Therefore, almost all forms of connective tissue diseases are related to PAH. In addition to general therapy and targeted drug therapy for PAH, high-dose glucocorticoid combined with immunosuppressant can quickly alleviate and stabilize the basic CTD-PAH disease. Given this, the development of therapeutic approaches targeting immune dysregulation and heightened inflammation is recognized as a promising strategy to prevent or reverse the progression of CTD-PAH. This review explores the potential mechanisms by which immune cells contribute to the development of CTD-PAH and examines the clinical application of immunosuppressive therapies in managing CTD-PAH.

References

Joshi S, Liu J, Bloom T, Atabay E, Kuo T, Lee M . Sotatercept analog suppresses inflammation to reverse experimental pulmonary arterial hypertension. Sci Rep. 2022; 12(1):7803. PMC: 9098455. DOI: 10.1038/s41598-022-11435-x. View

Savale L, Tu L, Rideau D, Izziki M, Maitre B, Adnot S . Impact of interleukin-6 on hypoxia-induced pulmonary hypertension and lung inflammation in mice. Respir Res. 2009; 10:6. PMC: 2644669. DOI: 10.1186/1465-9921-10-6. View

Bhattacharyya S, Wei J, Varga J . Understanding fibrosis in systemic sclerosis: shifting paradigms, emerging opportunities. Nat Rev Rheumatol. 2011; 8(1):42-54. PMC: 3954787. DOI: 10.1038/nrrheum.2011.149. View

Tan S, Krasnow M . Developmental origin of lung macrophage diversity. Development. 2016; 143(8):1318-27. PMC: 4852511. DOI: 10.1242/dev.129122. View

Ugor E, Simon D, Almanzar G, Pap R, Najbauer J, Nemeth P . Increased proportions of functionally impaired regulatory T cell subsets in systemic sclerosis. Clin Immunol. 2017; 184:54-62. DOI: 10.1016/j.clim.2017.05.013. View

Khanna D, Denton C, Jahreis A, van Laar J, Frech T, Anderson M . Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial. Lancet. 2016; 387(10038):2630-2640. DOI: 10.1016/S0140-6736(16)00232-4. View

Perros F, Dorfmuller P, Montani D, Hammad H, Waelput W, Girerd B . Pulmonary lymphoid neogenesis in idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med. 2011; 185(3):311-21. DOI: 10.1164/rccm.201105-0927OC. View

Sun C, Chen S . RGC32 Promotes Bleomycin-Induced Systemic Sclerosis in a Murine Disease Model by Modulating Classically Activated Macrophage Function. J Immunol. 2018; 200(8):2777-2785. PMC: 5893351. DOI: 10.4049/jimmunol.1701542. View

Moreno-Moral A, Bagnati M, Koturan S, Ko J, Fonseca C, Harmston N . Changes in macrophage transcriptome associate with systemic sclerosis and mediate contribution to disease risk. Ann Rheum Dis. 2018; 77(4):596-601. PMC: 5890626. DOI: 10.1136/annrheumdis-2017-212454. View

10.

Condliffe R, Kiely D, Peacock A, Corris P, Gibbs J, Vrapi F . Connective tissue disease-associated pulmonary arterial hypertension in the modern treatment era. Am J Respir Crit Care Med. 2008; 179(2):151-7. DOI: 10.1164/rccm.200806-953OC. View

11.

Thoreau B, Chaigne B, Renaud A, Mouthon L . Pathophysiology of systemic sclerosis. Presse Med. 2021; 50(1):104087. DOI: 10.1016/j.lpm.2021.104087. View

12.

Mulhearn B, Tansley S, McHugh N . Autoantibodies in connective tissue disease. Best Pract Res Clin Rheumatol. 2019; 34(1):101462. DOI: 10.1016/j.berh.2019.101462. View

13.

Lambrecht B, Hammad H . The role of dendritic and epithelial cells as master regulators of allergic airway inflammation. Lancet. 2010; 376(9743):835-43. DOI: 10.1016/S0140-6736(10)61226-3. View

14.

Wang R, Yuan T, Wang J, Chen Y, Zhao J, Li M . Immunity and inflammation in pulmonary arterial hypertension: From pathophysiology mechanisms to treatment perspective. Pharmacol Res. 2022; 180:106238. DOI: 10.1016/j.phrs.2022.106238. View

15.

Yuan K, Shamskhou E, Orcholski M, Nathan A, Reddy S, Honda H . Loss of Endothelium-Derived Wnt5a Is Associated With Reduced Pericyte Recruitment and Small Vessel Loss in Pulmonary Arterial Hypertension. Circulation. 2018; 139(14):1710-1724. PMC: 6443444. DOI: 10.1161/CIRCULATIONAHA.118.037642. View

16.

Stifano G, Christmann R . Macrophage Involvement in Systemic Sclerosis: Do We Need More Evidence?. Curr Rheumatol Rep. 2015; 18(1):2. DOI: 10.1007/s11926-015-0554-8. View

17.

Rhee R, Gabler N, Sangani S, Praestgaard A, Merkel P, Kawut S . Comparison of Treatment Response in Idiopathic and Connective Tissue Disease-associated Pulmonary Arterial Hypertension. Am J Respir Crit Care Med. 2015; 192(9):1111-7. PMC: 4642205. DOI: 10.1164/rccm.201507-1456OC. View

18.

Yaku A, Inagaki T, Asano R, Okazawa M, Mori H, Sato A . Regnase-1 Prevents Pulmonary Arterial Hypertension Through mRNA Degradation of Interleukin-6 and Platelet-Derived Growth Factor in Alveolar Macrophages. Circulation. 2022; 146(13):1006-1022. DOI: 10.1161/CIRCULATIONAHA.122.059435. View

19.

Preston I, Lewis D, Gomberg-Maitland M . Using Sotatercept in the Care of Patients With Pulmonary Arterial Hypertension. Chest. 2024; 166(3):604-611. DOI: 10.1016/j.chest.2024.06.3801. View

20.

Khangoora V, Bernstein E, King C, Shlobin O . Connective tissue disease-associated pulmonary hypertension: A comprehensive review. Pulm Circ. 2023; 13(4):e12276. PMC: 10711418. DOI: 10.1002/pul2.12276. View